Skip to main content

Psychostimulants Beneficial for Amphetamine-Type Stimulant Use Disorder

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 4, 2023.

By Elana Gotkine HealthDay Reporter

MONDAY, Dec. 4, 2023 -- For individuals with amphetamine-type stimulant use disorder (ATSUD), prescription psychostimulants (PPs) may reduce ATS use and craving, according to a review published in the November issue of Addiction.

Heidar Sharafi, Ph.D., from the Centre Hospitalier de l'Université de Montréal, and colleagues pooled results from randomized placebo-controlled trials (RCTs) to assess the efficacy and safety of PPs for ATSUD. The meta-analysis included 10 RCTs with 561 participants; seven trials studied methylphenidate and three studied dextroamphetamine for two to 24 weeks.

The researchers found that end-point craving was significantly decreased with PPs (standardized mean difference, –0.29), while the decrease was not statistically significant for ATS use, as assessed by urine analysis. No effect was seen for self-reported ATS use, retention in treatment, dropout following adverse events, early-stage craving, withdrawal, or depressive symptoms. After removing studies with a high risk for bias, treatment was associated with a significant reduction in urine analysis positive for ATS in sensitivity analysis. There was a negative association seen for methylphenidate and high doses of PPs with ATS use by urine analysis in subgroup analyses, while longer retention was seen in association with higher doses of PPs and treatment duration (≥20 weeks).

"Our results suggest that relatively potent PP agonists, especially when used in high doses, may be more effective than placebo in diminishing ATS use, increasing retention in treatment and decreasing craving among individuals with ATSUD," the authors write.

Several authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

2017 to 2022 Saw Rise in Cannabis-Related Disorder Encounters in Seniors

TUESDAY, June 18, 2024 -- From 2017 to 2022, there was an increase in the rates of cannabis-related disorder encounters among U.S. Medicare beneficiaries aged 65 years or older...

One in Six Primary Care Patients Report Cannabis Use

FRIDAY, June 7, 2024 -- One in six adult primary care patients report using cannabis, according to a study published online June 5 in JAMA Network Open. Lillian Gelberg...

32 Percent of U.S. Adults Know Someone Who Died of a Drug Overdose

MONDAY, June 3, 2024 -- Thirty-two percent of U.S. adults report knowing someone who died of a drug overdose, according to a study published online May 31 in JAMA Health...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.